These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 37991848)

  • 41. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.
    Du Y; Xu Y; Feng J; Hu L; Zhang Y; Zhang B; Guo W; Mai R; Chen L; Fang J; Zhang H; Peng T
    Vaccine; 2021 Apr; 39(16):2280-2287. PubMed ID: 33731271
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants.
    Wang Q; Yang C; Yin L; Sun J; Wang W; Li H; Zhang Z; Chen S; Liu B; Liu Z; Shi L; Liu X; Guan S; Wang C; Qu L; Feng Y; Niu X; Feng L; Zhao J; Li P; Chen L; Zhong N
    Signal Transduct Target Ther; 2023 Apr; 8(1):167. PubMed ID: 37069171
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response.
    Niu L; Chu LY; Burton SA; Hansen KJ; Panyam J
    J Control Release; 2019 Jan; 294():268-278. PubMed ID: 30572036
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Positive Correlation of the Enhanced Immune Response to PCV2 Subunit Vaccine by Conjugation of Chitosan Oligosaccharide with the Deacetylation Degree.
    Zhang G; Cheng G; Jia P; Jiao S; Feng C; Hu T; Liu H; Du Y
    Mar Drugs; 2017 Jul; 15(8):. PubMed ID: 28933754
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral Probiotic Vaccine Expressing Koi Herpesvirus (KHV) ORF81 Protein Delivered by Chitosan-Alginate Capsules Is a Promising Strategy for Mass Oral Vaccination of Carps against KHV Infection.
    Huang X; Ma Y; Wang Y; Niu C; Liu Z; Yao X; Jiang X; Pan R; Jia S; Li D; Guan X; Wang L; Xu Y
    J Virol; 2021 May; 95(12):. PubMed ID: 33827944
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence.
    Focosi D; Maggi F; Casadevall A
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215783
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522.
    Rose F; Wern JE; Gavins F; Andersen P; Follmann F; Foged C
    J Control Release; 2018 Feb; 271():88-97. PubMed ID: 29217176
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systemic Neutralizing Antibodies and Local Immune Responses Are Critical for the Control of SARS-CoV-2.
    Chandrasekar SS; Phanse Y; Riel M; Hildebrand RE; Hanafy M; Osorio JE; Abdelgayed SS; Talaat AM
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
    Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ
    J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhanced resistance to coxsackievirus B3-induced myocarditis by intranasal co-immunization of lymphotactin gene encapsulated in chitosan particle.
    Yue Y; Xu W; Hu L; Jiang Z; Xiong S
    Virology; 2009 Apr; 386(2):438-47. PubMed ID: 19233446
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhanced Immune Responses to Mucosa by Functionalized Chitosan-Based Composite Nanoparticles as a Vaccine Adjuvant for Intranasal Delivery.
    Lin Y; Sun B; Jin Z; Zhao K
    ACS Appl Mater Interfaces; 2022 Nov; 14(47):52691-52701. PubMed ID: 36382954
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans.
    Jeyanathan M; Fritz DK; Afkhami S; Aguirre E; Howie KJ; Zganiacz A; Dvorkin-Gheva A; Thompson MR; Silver RF; Cusack RP; Lichty BD; O'Byrne PM; Kolb M; Medina MFC; Dolovich MB; Satia I; Gauvreau GM; Xing Z; Smaill F
    JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34990408
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bicistronic DNA vaccine macromolecule complexed with poly lactic-co-glycolic acid-chitosan nanoparticles enhanced the mucosal immunity of Labeo rohita against Edwardsiella tarda infection.
    Leya T; Ahmad I; Sharma R; Tripathi G; Kurcheti PP; Rajendran KV; Bedekar MK
    Int J Biol Macromol; 2020 Aug; 156():928-937. PubMed ID: 32289420
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chitosan oligosaccharide improves the mucosal immunity of small intestine through activating SIgA production in mice: Proteomic analysis.
    Wen J; Niu X; Chen S; Chen Z; Wu S; Wang X; Yong Y; Liu X; Yu Z; Ma X; Abd El-Aty AM; Ju X
    Int Immunopharmacol; 2022 Aug; 109():108826. PubMed ID: 35569308
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2.
    Park KS; Bazzill JD; Son S; Nam J; Shin SW; Ochyl LJ; Stuckey JA; Meagher JL; Chang L; Song J; Montefiori DC; LaBranche CC; Smith JL; Xu J; Moon JJ
    J Control Release; 2021 Feb; 330():529-539. PubMed ID: 33358977
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus.
    Moon HJ; Lee JS; Talactac MR; Chowdhury MY; Kim JH; Park ME; Choi YK; Sung MH; Kim CJ
    Vet Microbiol; 2012 Dec; 160(3-4):277-89. PubMed ID: 22763171
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
    Freitag TL; Fagerlund R; Karam NL; Leppänen VM; Ugurlu H; Kant R; Mäkinen P; Tawfek A; Jha SK; Strandin T; Leskinen K; Hepojoki J; Kesti T; Kareinen L; Kuivanen S; Koivulehto E; Sormunen A; Laidinen S; Khattab A; Saavalainen P; Meri S; Kipar A; Sironen T; Vapalahti O; Alitalo K; Ylä-Herttuala S; Saksela K
    Vaccine; 2023 May; 41(20):3233-3246. PubMed ID: 37085458
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses.
    Gallorini S; Taccone M; Bonci A; Nardelli F; Casini D; Bonificio A; Kommareddy S; Bertholet S; O'Hagan DT; Baudner BC
    Vaccine; 2014 Apr; 32(20):2382-8. PubMed ID: 24434044
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.
    Wang M; Yue Y; Dong C; Li X; Xu W; Xiong S
    Clin Vaccine Immunol; 2013 Nov; 20(11):1743-51. PubMed ID: 24027262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.